Boehringer Ingelheim Archives

Home Boehringer Ingelheim

Latest Posts

News and Trends 22 Jun 2023

FDA approves type 2 diabetes drug for children 10 and older

The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years…

June 22, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 21 Apr 2023

RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy

RetinAI Medical AG, which creates clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is partnering with Boehringer Ingelheim. The companies aim to improve…

April 21, 2023 - 2 minutesmins - By Jim Cornall

Best in Biotech 9 Mar 2023

5 advancements in kidney disease research over the past year

Prevalent in millions of people across the globe, kidney diseases manifest through various symptoms like blood and excess protein in urine, fluid retention causing swollen ankles, poor appetite and even…

March 9, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie.…

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

migraine biotech cgrps heptares review neurology

News and Trends 17 Mar 2016

A Relief for Migraines at last? The Biotech race for the Ultimate Cure

A Migraine is more than just a headache; it is a neurological disorder affecting a staggering 10% of the worldwide population. So where are we on fighting a viable therapy…

March 17, 2016 - 4 minutesmins - By Ekaterina Perets

News and Trends 9 Jan 2023

Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies

Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will…

January 9, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the…

September 2, 2022 - 2 minutesmins - By Liza Laws

Diagnostic Test Mobidiag Antimicrobial Resistance

News and Trends 7 Jul 2022

Three companies join forces to tackle antimicrobial resistance (AMR)

A joint venture to create the next generation of antimicrobials, along with actionable diagnostics to fight AMR, has been announced between one French and two German companies. Research drive biopharmaceutical…

July 7, 2022 - 4 minutesmins - By Liza Laws

In Depth 22 Nov 2021

How Will We Be Treating Cystic Fibrosis 10 Years From Now?

Current treatments for cystic fibrosis are not suitable for all patients and have a limited effect on this life-threatening disease. But new advances in the field promise to overcome these…

November 22, 2021 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 May 2021

ADC Approval Buoys Spirits in Cancer Treatment Space

The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the…

May 11, 2021 - 7 minutesmins - By Jonathan Smith

boehringer ingelheim cancer vaccine amal therapeutics

News and Trends 16 Jul 2019

Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal

The German giant Boehringer Ingelheim has acquired the Swiss company AMAL Therapeutics and its cancer vaccine technology in a deal worth up to €325M. The deal includes €225M in upfront…

July 16, 2019 - 2 minutesmins - By Jonathan Smith

Boehringer Ingelheim ViraTherapeutics oncolytic virus

More News! 13 Sep 2018

Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company

Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian biotech company developing oncolytic viral therapies for cancer. ViraTherapeutics develops cancer therapies based on viruses…

September 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

Download Inpart’s latest report

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inpart, the leading platform for biopharma partnering